Management of Adverse Effects

Introduction to Adverse Effects Management

The American College of Physicians and other guideline societies recommend a comprehensive approach to managing adverse effects, including pain management, dose adjustment, and specialist referral, with consideration of the underlying condition and potential complications 1, 2, 3

For pain relief, acetaminophen or NSAIDs are recommended if no contraindications are present, according to the American College of Physicians 1
Tirzepatide should be resumed at a lower dose after symptoms resolve, with close monitoring of creatine kinase (CK) levels weekly until normalized, as suggested by 2
If a patient is also on statin therapy, consider temporarily discontinuing both medications, monitoring CK levels closely, and restarting medications sequentially after symptoms resolve, as recommended by 2, 4

The American Society of Clinical Oncology suggests urgent referral to rheumatology or neurology for severe cases, and consideration of alternative therapies, including GLP-1 agonists with different structures 3
Consider prednisone 0.5-1 mg/kg/day if CK levels are greater than 3 times the upper limit of normal, with hospitalization if severe weakness limiting mobility or signs of rhabdomyolysis are present, as recommended by 3
Early rheumatology or neurology consultation is essential for severe cases, according to the American Society of Clinical Oncology 3

Myositis is characterized by muscle weakness, elevated muscle enzymes, and inflammatory changes on diagnostic testing, with primary symptoms including muscle weakness in proximal extremities, difficulties standing up, lifting arms, and moving around, as reported by the European League Against Rheumatism and the American College of Rheumatology 5, 6, 3
Comprehensive laboratory evaluation for myositis should include muscle enzymes (CK, AST, ALT, LDH, aldolase), inflammatory markers (ESR, CRP), and consideration of myositis-associated autoantibodies, as recommended by the American College of Rheumatology 7
Myositis can have markedly elevated CK levels (median 2650 IU/L, range 335-20,270 IU/L) and elevated inflammatory markers, with MRI showing increased intensity and edema in affected muscles and EMG showing muscle fibrillations indicative of myopathy, as reported by 7

Overlooking cardiac involvement in polymyositis can be life-threatening, emphasizing the importance of thorough evaluation, according to the American College of Cardiology 3
Cardiac evaluation should include cardiac troponin, electrocardiography, and possibly cardiac MRI if abnormalities are detected, as suggested by the European Society of Cardiology and the American Heart Association 7, 3
Troponin should be checked to evaluate for cardiac involvement in patients with polymyositis, as recommended by the American Heart Association 3

Treatment for myositis may involve immediate discontinuation of triggering agents, high-dose corticosteroids (1-2 mg/kg/day, sometimes IV pulse therapy), and consideration of additional immunosuppressive therapy, including IVIG, plasma exchange, and steroid-sparing agents, as recommended by the National Institute of Neurological Disorders and Stroke 8
Immune checkpoint inhibitor-related myositis can be particularly severe with higher mortality rates (20% vs <10% for idiopathic inflammatory myositis), and bulbar symptoms or respiratory failure may indicate severe myositis or associated myasthenia gravis, as reported by the American Academy of Neurology 5, 7
The American Society of Clinical Oncology notes that PD-1/PD-L1 inhibitors are more commonly associated with myositis than CTLA-4 inhibitors, according to high-quality evidence 3

Mistaking myositis for simple myalgia can delay critical treatment, and failing to check CK levels in patients with muscle pain can lead to incomplete evaluation, as warned by the American College of Rheumatology 3, 5, 6
Overlooking complications, such as cardiac involvement in myositis, and using NSAIDs alone for true inflammatory myositis can be inadequate, and delayed referral to specialists (rheumatology, neurology) can worsen outcomes, as noted by the European League Against Rheumatism 5, 6